WhiteOak Capital Pharma and Healthcare Fund
The Scheme seeks to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies.
Growthvine rating: 2/5 — ranked #63 of 85 in category.
Fund basics
| Category | Equity: Sectoral |
|---|
| NAV | ₹16.44 (as of 2026-10-01) |
|---|
| AUM | ₹902 Cr |
|---|
| Expense ratio | 1.96% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Ramesh Mantri |
|---|
| Exit load | 0 |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −15.62% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 110.6% of NIFTY Pharma's upside and 85.7% of its downside.
Market cap allocation
| Large cap | 32.7% |
|---|
| Mid cap | 23.0% |
|---|
| Small cap | 44.3% |
|---|
Concentration
| Top 5 holdings | 31.1% |
|---|
| Top 10 holdings | 46.3% |
|---|
| Total holdings | 50 |
|---|
Top holdings
- Divis Laboratories Ltd. — 8.4%
- Sun Pharmaceutical Industries Ltd. — 7.4%
- Torrent Pharmaceuticals Ltd. — 6.8%
- Apollo Hospitals Enterprises Ltd. — 4.7%
- Laurus Labs Limited — 3.8%
- Sai Life Sciences Limited — 3.3%
- Cipla Ltd. — 3.3%
- Max Healthcare Institute Limited — 3.0%
- Neuland Laboratories Limited. — 2.9%
- Ipca Laboratories Ltd. — 2.7%
Top sectors
- Pharma & Biotech — 59.4%
- Healthcare — 28.9%
- Cash — 3.8%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 19.7% | Q1 (Top) | #4 of 76 |
| 2025 | 0.1% | Q2 | #34 of 69 |